Evidence map›Paper›PMID 26837803›Full record

ArticleInternational journal of technology assessment in health care2015

UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH.

Adrian Towse, Bengt Jonsson, Clare McGrath, Anne Mason, Ruth Puig-Peiro, Jorge Mestre-Ferrandiz, Michele Pistollato, Nancy Devlin

Open access · hybridAbstract read
In one paragraph

Article in International journal of technology assessment in health care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH.International journal of technology assessment in health care · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Adrian TowseOffice of Health Economicsatowse@ohe.org.
Bengt JonssonStockholm School of Economics.
Clare McGrathAstraZeneca.
Anne MasonUniversity of York.
Ruth Puig-PeiroServei Català de la Salut (CatSalut).
Jorge Mestre-FerrandizOffice of Health Economics.
Michele PistollatoOffice of Health Economics.
Nancy DevlinOffice of Health Economics.
Office Of Health Economics · GBAstraZeneca (Brazil) · BRServei de Salut de les Illes Balears · ESStockholm School of Economics · SEUniversity of York · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRelative effectiveness has become a key concern of health policy. In Europe, this is because of the need for early information to guide reimbursement and funding decisions about new medical technologies. However, ways that effectiveness (does it work?) and efficacy (can it work?) might differ across health systems are poorly understood.

methodsThis study proposes an analytical framework, drawing on production function theory, to systematically identify and quantify the determinants of relative effectiveness and sources of variation between populations and healthcare systems. We consider how methods such as stochastic frontier analysis and data envelopment analysis using a Malmquist productivity index could in principle be used to generate evidence on, and improve understanding about, the sources of variation in relative effectiveness between countries and over time.

resultsBetter evidence on factors driving relative effectiveness could: inform decisions on how to best use a new technology to maximum effectiveness; establish the need if any for follow-up post-launch studies, and provide evidence of the impact of new health technologies on outcomes in different healthcare systems.

conclusionsThe health production function approach for assessment of relative effectiveness is complementary to traditional experimental and observational studies, focusing on identifying, collecting, and analyzing data at the national level, enabling comparisons to take place. There is a strong case for exploring the use of this approach to better understand the impact of new medicines and devices for improvements in health outcomes.

Indexed as

Comparative Effectiveness ResearchCost-Benefit AnalysisHealth PolicyDecision MakingEfficiencyEuropeTechnology Assessment, BiomedicalDrug evaluationEuropean UnionRelative effectiveness

Identifiers

PMID26837803
PMCPMC4824958
OpenAlexW2254413333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.